Cardiogen Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Cardiogen dosing — protocols, safety, and where to buy.
Dose Range
10 mg oral capsule, 1-2 daily for 10-30 days
Dosage Calculator
Calculate exact dosing for Cardiogen.
Dosing Protocols
Beginner Cardiogen Protocol (first cardiovascular-focused cycle)
- Product form: 20 mg oral capsule from vendor with third-party HPLC and certificate of analysis.
- Dose: 1 capsule (20 mg) once daily, sublingual or oral on empty stomach 30–45 minutes before breakfast.
- Duration: 10 consecutive days, then stop.
- Washout: 60 days before repeat cycle.
- Monitoring: Baseline BP (ideally home morning and evening readings for 7 days pre-cycle), resting heart rate, subjective energy, exertional tolerance. Track through cycle and 4 weeks post-cycle.
- Baseline labs if not recent: Fasting lipid panel, HbA1c, comprehensive metabolic panel, CBC. If cardiac patient, have recent echocardiogram, ECG, and cardiology workup.
- Continue all existing cardiac medications. Do not stop β-blockers, ACE inhibitors/ARBs, statins, antiplatelets, or any other guideline-directed therapy to test Cardiogen alone.
- Stop criteria: New chest pain, palpitations, dyspnoea on exertion beyond baseline, syncope or near-syncope, new irregular pulse, marked BP changes (>20 mmHg systolic change), rash, or any new cardiovascular symptom. Cardiogen cycles should not produce cardiac side effects.
- When to call cardiology: New chest pain, new arrhythmia symptoms, or unexpected cardiovascular symptoms during a Cardiogen cycle warrant immediate cardiology consultation.
- Setting expectations: Most users report mild subjective effects (slightly improved energy, marginal exertional tolerance). Do not expect transformative improvement. Hard cardiac endpoints will not change from a 10-day bioregulator cycle.
- Cost perspective: One cycle of Cardiogen costs roughly 40–100 USD. Compare to the annual cost of optimised cardiac pharmacotherapy — the evidence-based stack delivers dramatically more cardiovascular benefit per dollar.
Intermediate Cardiogen Protocol (experienced bioregulator user, stable cardiac status)
- Product form: 20 mg oral capsule or lyophilised synthetic AEDR peptide (requires reconstitution).
- Dose: 20 mg oral/sublingual daily OR 2–5 mg SC daily.
- Duration: 10 consecutive days per cycle.
- Cycling: Twice yearly — autumn and spring typical.
- Rotation with other bioregulators: Space Cardiogen cycles from other Khavinson peptides by at least 2 months. A typical rotation runs Epitalon → washout → Cardiogen → washout → Pinealon → washout across the year.
- Monitoring: Home BP twice daily during cycles, resting HR daily, symptom diary. Annual echocardiogram if baseline cardiac disease. Annual ECG. Quarterly lipid panel if on statin therapy.
- Cardiology coordination: If established cardiac disease, notify cardiologist of bioregulator cycles. They should be aware even if not endorsing the protocol.
- Stack integration: Continue evidence-graded cardiac therapy. Bioregulator is an experimental layer, not a substitute.
- What to expect: Subjective effects remain modest. Some users report better exertional tolerance, subjective energy, or sleep quality. Biochemical and echocardiographic endpoints rarely change measurably from individual cycles.
- Cost/benefit honesty: Annual Cardiogen rotation cost roughly 200–400 USD. The same budget applied to diet optimisation, exercise programming, or sleep improvement produces more measurable cardiovascular benefit for most users.
Advanced Cardiogen Protocol (Khavinson-style cardiovascular rotation)
For users with 6+ months of Khavinson bioregulator experience, stable baseline cardiac status, and close coordination with their cardiology team.
- Annual rotation:
- Month 1, Days 1–10: Cardiogen 20 mg oral/sublingual OR 5 mg SC daily.
- Months 2–3: Washout.
- Month 4, Days 1–10: Epitalon 5–10 mg SC daily.
- Months 5–6: Washout.
- Month 7, Days 1–10: Pinealon 10 mg oral/sublingual daily (brain and cerebrovascular).
- Months 8–9: Washout.
- Month 10, Days 1–10: Cardiogen repeat cycle.
- Months 11–12: Washout.
- Monitoring: Baseline and annual echocardiogram, 24-hour ambulatory BP monitoring, ECG. Annual fasting lipid/glucose/HbA1c panel, BNP if heart failure history. Daily home BP and HR during cycles.
- Stack layered on evidence-graded base: Continue blood pressure control, LDL reduction, antiplatelets where indicated, SGLT2 inhibitors or GLP-1 agonists if cardiometabolic, β-blockers post-MI, ACE inhibitor/ARB where indicated, aerobic exercise programme. The bioregulator rotation is the experimental 10th layer, not a substitute for the foundation.
- Coordinated with cardiology: Any cardiology visit should include disclosure of bioregulator cycles. Pharmacists should have a complete medication list including peptide cycles.
- Stop and reassess: If any cycle produces new cardiovascular symptoms, stop and consult cardiology. If annual echocardiogram or biomarker trends worsen beyond expected age-related changes, reconsider the bioregulator programme.
- Realistic expectation: The advanced protocol is a ritual layered on evidence-graded cardiac care. Users cannot reliably distinguish bioregulator effect from concurrent improvements in exercise, diet, stress management, or medication optimisation. Maintain the evidence-based foundation.
Commonly Stacked With
Stacking Notes
Cardiogen is most commonly cycled within the Khavinson multi-bioregulator rotation. Below we describe both the community pattern and the evidence-graded alternative.
Khavinson multi-bioregulator rotation
Within the Russian longevity and bioregulator community, Cardiogen is cycled alongside Pinealon, Epitalon, Thymogen, Vilon, Livagen, and Bronchogen in 10-day cycles with 60–90 day washouts. A cardiac-focused rotation might run:
- Days 1–10: Cardiogen 20 mg oral/sublingual daily
- Days 11–70: Washout
- Days 71–80: Epitalon 5–10 mg SC daily (general anti-aging and vascular)
- Days 81–140: Washout
- Days 141–150: Pinealon 10 mg oral daily (brain and cerebrovascular)
- Days 151–210: Washout
- Days 211–220: Cardiogen repeat cycle
The rationale — additive tissue-specific bioregulator effects — is theoretical, not empirically tested.
Evidence-graded cardiovascular stack (preferred)
For actual cardiovascular health, the evidence hierarchy looks completely different:
- Blood pressure control — amlodipine, ACE inhibitor/ARB, thiazide as indicated, target <130/80 mmHg.
- LDL-cholesterol reduction — statin first-line (rosuvastatin 20–40 mg or atorvastatin 40–80 mg), add ezetimibe 10 mg if target not met, add PCSK9 inhibitor (evolocumab, alirocumab) for high-risk patients.
- Antiplatelet therapy in established ASCVD — aspirin 81 mg daily or clopidogrel 75 mg daily.
- SGLT2 inhibitors — empagliflozin 10 mg, dapagliflozin 10 mg in heart failure and diabetes.
- GLP-1 agonists — Semaglutide, Tirzepatide for cardiometabolic risk.
- β-blockers post-MI and in HFrEF.
- Aerobic exercise 150+ min/week moderate intensity.
- Omega-3 fatty acids — icosapent ethyl 4 g daily (EPA-only prescription form) has RCT evidence in high-risk patients.
- Mediterranean dietary pattern.
Cardiogen does not displace any tier. It is a tier-10+ speculative add-on for users who have optimised tiers 1–9.
Stacking with cardiac medications
No pharmacokinetic interaction data exist. Theoretical considerations:
- β-blockers — no expected interaction. Continue maintenance therapy during Cardiogen cycles.
- ACE inhibitors / ARBs — no expected interaction.
- Statins — no expected interaction.
- Antiplatelets / anticoagulants — no known interaction. Watch for any unusual bleeding or bruising during cycles.
- SGLT2 inhibitors — no expected interaction.
- GLP-1 agonists — no expected interaction.
- Digoxin — narrow therapeutic index drug; do not add Cardiogen without cardiology approval.
- Antiarrhythmics (amiodarone, sotalol, dofetilide) — narrow therapeutic windows; coordinate with cardiologist.
Stacking with cardiovascular supplements
Common community combinations:
- Cardiogen + CoQ10 100–300 mg daily — theoretical mitochondrial support convergence
- Cardiogen + L-citrulline 3–6 g daily — complementary arginine-related NO pathway support
- Cardiogen + omega-3 EPA/DHA 2–4 g daily — anti-inflammatory cardiac support
- Cardiogen + Taurine 1–3 g daily — cardiac membrane stabilisation, modest evidence
- Cardiogen + Berberine 500 mg x 2–3 daily — lipid/glucose metabolic support
None of these combinations have been tested for synergy or interaction. They are compatible from a safety standpoint.
Contraindicated combinations
Do not substitute Cardiogen for acute coronary syndrome therapy. Do not use as monotherapy for hypertension, heart failure, or dyslipidaemia. Do not discontinue guideline-directed medical therapy to test Cardiogen alone. Do not use perioperatively around cardiac surgery without cardiology approval.
With other Khavinson bioregulators
Running Cardiogen alongside or sequentially with Epitalon, Pinealon, Thymogen, and other Khavinson tetrapeptides is the dominant community pattern. Safe at convention doses; no specific synergy evidence. If budget constrained, prioritise the bioregulator with strongest evidence for your goal.
Side Effects & Safety
Contraindications
## Contraindications ### Absolute contraindications - **Pregnancy** — no reproductive toxicology data - **Breastfeeding** — no excretion/infant safety data - **Paediatric use (<18)** — unquantified developmental effects - **Active acute coronary syndrome** — experimental peptides cannot substitute for ACS therapy - **Decompensated heart failure** — NYHA IV, acute decompensation, on inotropes - **High-grade AV block without pacemaker** — unquantified conduction effects - **Significant ventricular arrhythmia** — unquantified arrhythmogenic risk - **Active cardiac surgery or recent cardiac intervention** (within 6 weeks) — no perioperative safety data - **Known hypersensitivity** to Cardiogen or any Khavinson bioregulator ### Relative contraindications (supervised use only) - **Atrial fibrillation** — no interaction data with rate/rhythm-control drugs or anticoagulants - **Symptomatic bradycardia** — unknown effect on sinus node - **Prolonged QTc (>500 ms)** — no QTc safety data - **Severe aortic stenosis** — perioperative context often present - **Recent MI or stroke (within 3 months)** — acute recovery period, avoid experimental agents - **Severe renal impairment (eGFR <30)** — unknown PK in renal failure - **Decompensated hepatic disease (Child-Pugh B/C)** - **Solid organ transplant recipients** - **Active haematological or solid organ malignancy** ### Use with caution - **Multiple cardiac medications (polypharmacy)** — no interaction data, cardiology coordination advised - **Narrow-therapeutic-index cardiac drugs** (digoxin, antiarrhythmics, warfarin) — cardiology approval required - **Recent implanted cardiac device** (pacemaker, ICD, CRT) - **Home oxygen therapy or advanced cardiac disease** - **Age 80+** — increased polypharmacy and frailty risk ### Quality-of-supply contraindication Do not use Cardiogen from vendors without third-party HPLC peptide content confirmation and endotoxin testing. Grey-market peptide quality varies. Cheap unverified product is not worth the risk in a cardiovascular context. ### Symptoms that indicate evaluation, not bioregulators New chest pain, syncope, palpitations, exertional dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, peripheral oedema, or sudden weight gain are indications for prompt cardiology evaluation — not Cardiogen self-treatment. Do not use experimental bioregulators as substitutes for cardiovascular diagnostic workup.
Additional Notes
Dosage Notes
Cardiogen dosing derives from Khavinson-group Russian publications and post-Soviet commercial product labelling, not from modern cardiovascular pharmacokinetic studies.
Oral/sublingual dosing
- 1 capsule (20 mg nominal) once daily
- Sublingual preferred — hold under tongue ~60 seconds for partial buccal absorption before swallowing
- Empty stomach 30–45 min before first meal
- Duration: 10 days per cycle
- Washout: 60–90 days between cycles
20 mg capsule = undisclosed actual AEDR content (historically 2–4 mg).
Subcutaneous dosing
- 2–5 mg SC once daily from reconstituted synthetic peptide
- 10 consecutive days per cycle
- 60-day washout minimum between cycles
SC bypasses first-pass hydrolysis and delivers higher theoretical systemic exposure per mg.
Cycling rationale
The 10-on / 60-off pattern is uniform across Khavinson peptides. No dose-ranging or duration-comparison studies establish that 10 days is optimal.
Seasonal considerations
Russian clinicians favour autumn entry before winter — a period of increased cardiovascular stress (cold weather, respiratory infection, holiday-related dietary and activity changes). The timing is convention, not empirically optimised.
Maximum dose
No established maximum. Russian literature uses 20 mg oral consistently. Do not exceed 20 mg oral or 5 mg SC per day.
Continuous dosing
Do not run continuous cycles. Safety of continuous exposure has not been characterised.
Age considerations
Russian studies enrol older adults (65+) with established cardiovascular disease or risk. Younger adults with normal cardiac function have less theoretical benefit. No paediatric use.
Renal impairment
No formal dose adjustment published. Peptide is small and cleared via hydrolysis to amino acids and renal excretion. Avoid in significant renal impairment (eGFR <30) pending modern PK data.
Hepatic impairment
No formal dose adjustment. Avoid in decompensated hepatic disease.
Dosing around cardiac procedures
Do not use Cardiogen perioperatively around cardiac surgery, coronary intervention, or device implantation without explicit cardiology approval. Discontinue cycles at least 2 weeks before planned cardiac procedures pending pharmacokinetic data.
Frequently Asked Questions
What is the recommended Cardiogen dosage?
The typical dose range for Cardiogen is 10 mg oral capsule, 1-2 daily for 10-30 days. Always start with the lowest effective dose.
How often should I take Cardiogen?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Cardiogen need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Cardiogen side effects?
## Side Effects and Safety Cardiogen has been used in Russian clinical settings and post-Soviet supplement channels for roughly 20 years without a substantial adverse-event literature. That absence is reassuring in direction but must be contextualised against the limited denominator of formally documented human exposure (probably in the low thousands rather than the hundreds of thousands) and the absence of modern pharmacovigilance tracking. ### Reported short-term adverse effects Across Russian published series and post-marketing observations: - **Gastrointestinal:** mild nausea, occasional dyspepsia, infrequent epigastric discomfort. Typically self-limited. - **Cardiovascular:** no systematic reports of arrhythmia, blood pressure instability, or heart failure decompensation attributable to Cardiogen. Modest changes in resting heart rate have been reported in some series but not causally attributed. - **Headache:** occasional mild headache in the first days of a cycle. - **Fatigue and sleep:** variable; some users report improved energy during cycles. - **Rare allergic or hypersensitivity reactions:** occasional mild rash. No anaphylaxis in published literature. The reported profile is mild, but the total sample is small and the reporting systems are not uniform. Rare serious events are possible but would be detected only with larger pharmacovigilance programmes. ### Theoretical concerns - **Cardiac arrhythmia risk.** Cardiogen is proposed to modulate cardiomyocyte gene expression, potentially including ion channels (sodium, potassium, calcium). Off-target effects on repolarisation could theoretically produce arrhythmogenic changes. No QTc-interval data exist for Cardiogen from modern electrophysiological testing. - **Interaction with cardiac medications.** No formal pharmacokinetic or pharmacodynamic interaction studies with β-blockers, ACE inhibitors, ARBs, statins, antiplatelets, or anticoagulants have been conducted. The peptide's rapid hydrolysis makes pharmacokinetic interactions theoretically unlikely, but this is inference. - **Anti-fibrotic effects and myocardial remodelling.** If Cardiogen genuinely modulates cardiac remodelling, off-target effects on ventricular geometry, valvular function, or conduction system are possible. No imaging-based follow-up studies exist. ### Pregnancy and breastfeeding No reproductive toxicology data. Avoid in pregnancy and lactation. ### Paediatric use No paediatric safety data. Do not use in children or adolescents. ### Elderly with polypharmacy This is the population Russian clinicians target. It is also the group most vulnerable to drug-drug interactions. If on complex cardiac regimens (β-blocker + ACE inhibitor/ARB + diuretic + statin + antiplatelet ± anticoagulant ± SGLT2 inhibitor), discuss with the prescribing cardiologist before adding Cardiogen. The interaction risk is theoretically low but unmeasured. ### Active cardiovascular events Do not use Cardiogen as a substitute for acute coronary syndrome management, acute heart failure therapy, or urgent cardiovascular intervention. Acute events require evidence-graded urgent care. ### Arrhythmia and conduction disease Patients with significant arrhythmia (atrial fibrillation, high-grade AV block, ventricular arrhythmia, prolonged QTc) should not experiment with Cardiogen until modern cardiac safety characterisation exists. The theoretical arrhythmia risk is unquantified. ### Active cardiac surgery or recent intervention Do not use Cardiogen perioperatively around cardiac surgery, coronary intervention, or device implantation without explicit cardiology approval. Bleeding risk, anaesthetic interactions, and unmeasured pharmacokinetics combine to make this inappropriate. ### Severe heart failure Patients with advanced heart failure (NYHA class III–IV, decompensated, on inotropes, or awaiting transplant/LVAD) should manage their condition with evidence-based therapy. Cardiogen is not appropriate for these patients. ### Supply chain quality As with all Khavinson bioregulator peptides, product quality varies. Require third-party HPLC confirmation of peptide content and endotoxin testing. Unverified product should not be used — especially in a cardiac context where contaminated or mislabeled peptide could cause arrhythmia or other cardiac events. ### Overall assessment The signal as reported is mild, without serious adverse cardiac events at Russian-convention dosing. The safety profile as actually characterised by modern standards is effectively unknown. Treat Cardiogen as experimental, layered on top of (never substituted for) evidence-graded cardiac therapy, and watch for unexpected cardiovascular symptoms.
Where can I buy Cardiogen?
Visit our vendor directory to find trusted sources for Cardiogen.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.